Emerging health problems require rapid advice. We describe the development and pilot testing of a systematic, transparent approach used by the World Health Organization (WHO) to develop rapid advice guidelines in response to requests from member states confronted with uncertainty about the pharmacological management of avian influenza A (H5N1) virus infection. We first searched for systematic reviews of randomized trials of treatment and prevention of seasonal influenza and for non-trial evidence on H5N1 infection, including case reports and animal and in vitro studies. A panel of clinical experts, clinicians with experience in treating patients with H5N1, influenza researchers, and methodologists was convened for a two-day meeting. Panel members reviewed the evidence prior to the meeting and agreed on the process. It took one month to put together a team to prepare the evidence profiles (i.e., summaries of the evidence on important clinical and policy questions), and it took the team only five weeks to prepare and revise the evidence profiles and to prepare draft guidelines prior to the panel meeting. A draft manuscript for publication was prepared within 10 days following the panel meeting. Strengths of the process include its transparency and the short amount of time used to prepare these WHO guidelines. The process could be improved by shortening the time required to commission evidence profiles. Further development is needed to facilitate stakeholder involvement, and evaluate and ensure the guideline's usefulness.
Horton R (2002) WHO: The casualties and compromises of renewal. Lancet 359: 1605–1611.
[3]
Laing R, Waning B, Gray A, Ford N, 't Hoen E (2003) 25 years of the WHO essential medicines lists: Progress and challenges. Lancet 361: 1723–1729.
[4]
McCarthy M (2005) Critics slam draft WHO report on homoeopathy. Lancet 366: 705.
[5]
Shaneyfelt TM, Mayo-Smith MF, Rothwangl J (1999) Are guidelines following guidelines? The methodological quality of clinical practice guidelines in the peer-reviewed medical literature. JAMA 281: 1900–1905.
[6]
Grilli R, Magrini N, Penna A, Mura G, Liberati A (2000) Practice guidelines developed by specialty societies: The need for a critical appraisal. Lancet 355: 103–106.
[7]
Baverstock K (2003) A time to ask what you want of WHO. BMJ 327: 111.
[8]
Grol R, Dalhuijsen J, Thomas S, Veld C, Rutten G, et al. (1998) Attributes of clinical guidelines that influence use of guidelines in general practice: Observational study. BMJ 317: 858–861.
[9]
Woolf SH (1990) Practice guidelines: A new reality in medicine. I. Recent developments. Arch Intern Med 150: 1811–1818.
[10]
Global Programme on Evidence for Health Policy (2003) Guidelines for WHO guidelines. World Health Organization. Available: http://whqlibdoc.who.int/hq/2003/EIP_GPE？_EQC_2003_1.pdf. Accessed 5 April 2007.
[11]
(2002) Moving from evidence to action. In: Guyatt G, Rennie D, editors. Users' guide to the medical literature: A manual for evidence-based clinical practice. Chicago: AMA Press. editors.
[12]
Schünemann HJ, Munger H, Brower S, O'Donnell M, Crowther M, et al. (2004) Methodology for guideline development for the Seventh American College of Chest Physicians Conference on Antithrombotic and Thrombolytic Therapy: The Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest 126: 174S–178S.
[13]
Raine R, Sanderson C, Black N (2005) Developing clinical guidelines: A challenge to current methods. BMJ 331: 631–633.
[14]
National Institutes for Health and Clinical Excellence [www.nice.org.uk].
[15]
Moynihan R, Oxman A, Lavis J, Paulsen E (2006) Evidence-informed health policy: Using research to make health systems healthier. Oslo: Norwegian Knowledge Centre for the Health Services.
[16]
National Heart, Lung, and Blood Institute (2005) Research translation, dissemination, and application—Moving toward a new vision and strategic framework. Discussion and consensus findings. NHLBI Cardivascular Thought Leaders Meeting; 17 June 2005; Bethesda, Maryland, United States of America. Available: http://www.nhlbi.nih.gov/health/prof/hea？rt/other/cvd_tlead/cvd_tlead.pdf. Accessed 5 April 2007.
[17]
National Institute for Health and Clinical Excellence (2006) Independent experts from World Health Organisation to review NICE clinical guidelines programme. Available: http://www.nice.org.uk/page.aspx?o=31382？3. Accessed 5 April 2007.
[18]
Oxman AD, Fretheim A, Schünemann HJ (2006) Improving the use of research evidence in guideline development: Introduction. Health Res Policy Syst 4: 12.
[19]
Schünemann HJ, Fretheim A, Oxman AD (2006) Improving the use of research evidence in guideline development: 1. Review of guidelines for guidelines. Health Res Policy Syst 4: 13.
[20]
Schünemann HJ, Hill S, Kakad M, Bellamy R, Uyeki T, et al. (2007) WHO Rapid Advice Guidelines for the pharmacological management of sporadic human infection with avian influenza A (H5N1) virus. Lancet Infect Dis 7: 21–31.
[21]
World Health Organization (2006) WHO Rapid Advice Guidelines on pharmacological management of humans infected with avian influenza A (H5N1) virus. Available: http://www.who.int/medicines/publication？s/WHO_PSM_PAR_2006.6.pdf. Accessed 5 April 2007.
[22]
Atkins D, Best D, Briss PA, Eccles M, Falck-Ytter Y, et al. (2004) Grading quality of evidence and strength of recommendations. BMJ 328: 1490.
[23]
Schünemann HJ, Jaeschke J, Cook D, Bria WF, Fahy BF, et al. (2006) An official ATS statement: Grading the quality of evidence and strength of recommendations for guidelines and recommendations. Am J Respir Crit Care Med 174: 605–614.
[24]
Briss PA (2005) Evidence-based: US road and public-health side of the street. Lancet 365: 828–830.
